| 1 |
Presentation of the adopted annual financial statements, the approved consolidated financial statements and the combined management report for the Company and the Group, as well as the report of the Supervisory Board, in each case for the 2025 financial year respectively as of 31 December 2025 |
Informational(1.322)
|
| 2 |
Resolution on the appropriation of the balance sheet profit for the 2025 financial year |
✓ For(1.322)
|
| 3 |
Resolution on the approval of the actions of the Management Board |
✓ For(1.322)
|
| 4 |
Resolution on the approval of the actions of the Supervisory Board |
✓ For(1.322)
|
| 5 |
Resolution on the appointment of the auditor and the Group auditor for the 2026 financial year and the auditor for any audit or review of interim reports |
✓ For(1.322)
|
| 6 |
Resolution on the approval of the Compensation Report |
✓ For(1.322)
|
| 7 |
Resolution on the amendment of Section 9 para. 1 of the Articles of Association to increase the size of the Supervisory Board |
✓ For(1.322)
|
| 8 |
Resolution on Elections to the Supervisory Board |
|
| 8.1 |
Mr. Helmut Jeggle |
✓ For(1.322)
|
| 8.2 |
Prof. Dr. Anja Morawietz |
✓ For(1.322)
|
| 8.3 |
Prof. Dr. Rudolf Staudigl |
✓ For(1.322)
|
| 8.4 |
Dr. Susanne Schaffert |
✓ For(1.322)
|
| 8.5 |
Prof. Dr. Iris Loew-Friedrich |
✓ For(1.322)
|
| 9 |
Resolution on the amendment of Section 16 para. 5 of the Articles of Association to reauthorize the Management Board to provide for the holding of a virtual Annual General Meeting |
✓ For(1.322)
|
| 10 |
Resolution on the cancellation of the existing Authorized Capital 2025 and the creation of new Authorized Capital 2026 with the possibility of excluding subscription rights and corresponding amendment to the Articles of Association |
✓ For(1.322)
|
| 11 |
Resolution on the approval of the conclusion of a domination and profit and loss transfer agreement between BioNTech SE and BioNTech Discovery GmbH |
✓ For(1.322)
|
rebel Financial